Skip to main content
Clinical Trials/ACTRN12622000846729
ACTRN12622000846729
Recruiting
未知

A randomised controlled m-health trial evaluating the effect of gamification on physical activity, sleep quantity, and quality of life in young adults

niversity of Seville0 sites100 target enrollmentJune 16, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Physical inactivity
Sponsor
niversity of Seville
Enrollment
100
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 16, 2022
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Seville

Eligibility Criteria

Inclusion Criteria

  • To take part in the study, participants have to live in Seville (Spain), be 18–55 years of age and have access to an iOS or Android smartphone or tablet with internet access. Participants were recruited across the campus of the University of Seville, through social media and word of mouth.

Exclusion Criteria

  • Participants will be excluded if they had a diagnosis of a sleep disorder such as insomnia, obstructive sleep apnoea or narcolepsy, if they were taking any sleep\-aid medication or having any condition which would contraindicate participation in physical activity.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A randomised, controlled clinical trial assessing the efficacy of;Lanreotide to halt disease progression in ADPKDAutosomal Dominant Polycystic Kidney Diseasepolycystic kidney disease100383601001965410029149
NL-OMON39497niversitair Medisch Centrum Groningen300
Active, not recruiting
Not Applicable
To investigate the effect of Lanreotide on renal function decline in ADPKD patientsFirst, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.MedDRA version: 14.1Level: LLTClassification code 10023433Term: Kidney polycysticSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2011-005017-37-NLDIPAK Consortium
Terminated
Not Applicable
:DECIDE Study: Utilising technology for Diet & Exercise Change In complex chronic conditions across Diverse EnvironmentsCardiometabolic HealthSolid Organ Transplant RecipientsChronic Kidney DiseaseMetabolic SyndromeDiet and Nutrition - ObesityCardiovascular - Other cardiovascular diseasesPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationMetabolic and Endocrine - Other metabolic disorders
ACTRN12620001282976Princess Alexandra Hospital67
Not yet recruiting
Not Applicable
A clinical trial to study the effects of two procedures, shatpushpa siddha taila nasya and shatpushpa siddha taila matrabasti in patients with irregular menses and pcos.Health Condition 1: E282- Polycystic ovarian syndrome
CTRI/2024/03/063784Chaitalee Rajendra Jain
Terminated
Phase 3
Varenicline alone or with nicotine e-cigarettes for smoking cessation in people with mental illness and drug and/or alcohol dependence.SmokingMental illnessDrug and alcohol dependenceMental Health - AddictionMental Health - Other mental health disorders
ACTRN12616001355460The University of Auckland15